First patient randomised in NSCLC Phase II trial
The first patient has been randomised in a Phase II trial evaluating an oral microbiome therapy in combination with Cemiplimab to treat patients with advanced non-small cell lung cancer (NSCLC).
Maat033, an oral microbiome developed by biotechnology company MaaT Pharma, is being studied as a treatment in combination with Cemiplimab in enhancing disease control rate versus the best investigator’s choice (BIC) treatment.
The IMMUNOLIFE trial, sponsored by Gustave Roussy, will evaluate 162 patients with advanced NSCLC who are refractory to immune checkpoint inhibitors (ICIs) and have received antibiotics.
“Gut dysbiosis is increasingly recognised as a risk factor for immunoresistance to immunotherapy,” said Lisa Derosa, MD at Gustave Roussy and Coordinating Investigator of the IMMUNOLIFE trial.
“MaaT033 is designed to restore microbiome balance and may help improve patients’ response to treatment.”
“We have built substantial evidence in our haemato-oncology programmes that complex donor-derived products restore immune homeostasis in the context of pre-existing dysbiosis,” added Hervé Affagard, CEO and Co-Founder of MaaT Pharma.
“This study represents an opportunity to further explore these findings in immuno-oncology in a well-defined patient population expected to show antibiotic-mediated dysbiosis.”
The study includes 14 centres in France, with patient enrolment of approximately two years and total CB treatment duration of two years. Primary results after one-year follow-up post-treatment are expected in late 2030.
Bruno Quinney, Content Team, DDW
